Definium Therapeutics reports another positive Phase 3 readout for DT120 in generalised anxiety disorder, with randomized data from the Panorama study now toplined.

Definium Therapeutics reports Phase 3 topline success for LSD (DT120) in generalized anxiety disorder, following MDD progress. Here’s the clinical context and what DMV patients should watch.

FDA guidance, Phase 3 results and VA-led training signal psychedelic therapies edging closer to clinics. Here’s what practitioners—and DMV patients—should know now.

Resilient resubmits MDMA-assisted therapy to FDA, Definium reports positive oral LSD Phase 3 data in GAD, and Canada funds a C$24M cannabis–brain health consortium.